However, the use of ADCs in advanced HER2‐low breast cancer, such as the order of use of HER2‐targeted ADCs and TROP2‐targeted ADCs, is still controversial and needs to be verified by more clinical trials.30 This evidence concerns the gene TACSTD2 and breast cancer.